Martin Kbel

List of Publications by Year in Descending Order

202 papers	10,520 citations	56 h-index	97 g-index
227 ext. papers	12,829 ext. citations	6.3 avg, IF	5.9 L-index

#	Paper	IF	Citations
202	The Evolution of Ovarian Carcinoma Subclassification.. *Cancers*, **2022**, 14,	6.6	5
201	Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma. *International Journal of Gynecological Pathology*, **2022**, 41, 35-39	3.2	1
200	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. *International Journal of Gynecological Pathology*, **2022**, 41, 12-19	3.2	3
199	Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.. *Journal of Pathology*, **2022**,	9.4	1
198	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 217-228	4	7
197	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
196	Protracted clinical course of an AFF1 fusion positive uterine smooth muscle tumor causing diagnostic confusion over a course of 15 years.. *Gynecologic Oncology Reports*, **2021**, 38, 100890	1.3	
195	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
194	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
193	Adenocarcinoma of the Uterine Cervix: Immunohistochemical Biomarker Expression and Diagnostic Performance. *Applied Immunohistochemistry and Molecular Morphology*, **2021**, 29, 209-217	1.9	0
192	Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma. *International Journal of Gynecological Pathology*, **2021**, 40, 116-123	3.2	13
191	The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting. *International Journal of Gynecological Pathology*, **2021**, 40, 32-40	3.2	8
190	Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma. *International Journal of Gynecological Pathology*, **2021**,	3.2	1
189	Embryonic protein NODAL regulates the breast tumor microenvironment by reprogramming cancer-derived secretomes. *Neoplasia*, **2021**, 23, 375-390	6.4	2
188	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. *Cancer*, **2021**, 127, 2409-2422	6.4	14
187	Targeting the actin/tropomyosin cytoskeleton in epithelial ovarian cancer reveals multiple mechanisms of synergy with anti-microtubule agents. *British Journal of Cancer*, **2021**, 125, 265-276	8.7	1
186	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2

185	Implications for management of ovarian cancer in a transgender man: Impact of androgens and androgen receptor status. *Gynecologic Oncology*, **2021**, 161, 342-346	4.9	1
184	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. *Carcinogenesis*, **2021**, 42, 785-793	4.6	1
183	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	9.8	3
182	Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix. *Histopathology*, **2021**, 79, 160-167	7.3	3
181	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
180	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. *Modern Pathology*, **2021**, 34, 1008-1016	9.8	8
179	SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma. *Journal of Pathology: Clinical Research*, **2021**, 7, 144-153	5.3	10
178	p53 immunohistochemical analysis of fusion-positive uterine sarcomas. *Histopathology*, **2021**, 78, 805-813	7.3	6
177	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. *Journal of Pathology*, **2021**, 253, 41-54	9.4	15
176	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. *Gynecologic Oncology*, **2021**, 162, 421-430	4.9	1
175	Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening. *American Journal of Surgical Pathology*, **2021**, 45, 1452-1463	6.7	4
174	Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features. *Journal of Pathology: Clinical Research*, **2021**,	5.3	2
173	Histological and molecular diversity and heterogeneity of precancerous lesions associated with inflammatory bowel diseases. *Journal of Clinical Pathology*, **2020**, 73, 391-402	3.9	10
172	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. *Journal of Pathology: Clinical Research*, **2020**, 6, 252-262	5.3	16
171	Loss of switch/sucrose non-fermenting complex protein expression in undifferentiated gastrointestinal and pancreatic carcinomas. *Histopathology*, **2020**, 77, 46-54	7.3	20
170	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
169	Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to T Cell Cytotoxicity. *Frontiers in Immunology*, **2020**, 11, 1287	8.4	5
168	Low junctional adhesion molecule-A expression is associated with an epithelial to mesenchymal transition and poorer outcomes in high-grade serous carcinoma of uterine adnexa. *Modern Pathology*, **2020**, 33, 2361-2377	9.8	3

167	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
166	PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer. *Gynecologic Oncology*, **2020**, 158, 776-784	4.9	8
165	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. *Gynecologic Oncology*, **2020**, 157, 36-45	4.9	5
164	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. *Gynecologic Oncology*, **2020**, 157, 12-20	4.9	7
163	High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. *Human Pathology*, **2020**, 98, 56-63	3.7	2
162	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. *PLoS ONE*, **2020**, 15, e0240412	3.7	1
161	Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas. *Current Drug Targets*, **2020**, 21, 974-995	3	2
160	Newly recognized non-adenomatous lesions associated with enteric carcinomas in inflammatory bowel disease - Report of six rare and unique cases. *Annals of Diagnostic Pathology*, **2020**, 44, 151455	2.2	3
159	Therapeutic options for mucinous ovarian carcinoma. *Gynecologic Oncology*, **2020**, 156, 552-560	4.9	21
158	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. *International Journal of Gynecological Pathology*, **2020**, 39, 537-545	3.2	8
157	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. *Journal of Pathology*, **2020**, 250, 336-345	9.4	56
156	Ovarian cancer: diagnostic accuracy and tumor types distribution in East Africa compared to North America. *Diagnostic Pathology*, **2020**, 15, 86	3	1
155	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin **2020**, 8,		7
154	Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma. *Clinical Cancer Research*, **2020**, 26, 5400-5410	12.9	23
153	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
152	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
151	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		
150	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line **2020**, 15, e0240412		

149	The molecular origin and taxonomy of mucinous ovarian carcinoma. *Nature Communications*, **2019**, 10, 3935	17.4	59
148	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. *Modern Pathology*, **2019**, 32, 1834-1846	9.8	21
147	Oncogenic mutations in histologically normal endometrium: the new normal?. *Journal of Pathology*, **2019**, 249, 173-181	9.4	60
146	Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. *Clinical Cancer Research*, **2019**, 25, 3962-3973	12.9	16
145	Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma. *Clinical Cancer Research*, **2019**, 25, 4309-4319	12.9	17
144	A COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma. *Journal of Pathology: Clinical Research*, **2019**, 5, 177-188	5.3	8
143	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. *International Journal of Gynecological Pathology*, **2019**, 38, 353-362	3.2	25
142	FIGO Stage Is the Strongest Prognostic Factor in Adenocarcinoma of the Uterine Cervix. *Journal of Obstetrics and Gynaecology Canada*, **2019**, 41, 1318-1324	1.3	6
141	Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma. *Frontiers in Oncology*, **2019**, 9, 1570	5.3	11
140	Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon. *American Journal of Surgical Pathology*, **2019**, 43, 531-537	6.7	15
139	Ovarian Endometrioid Carcinoma Misdiagnosed as Mucinous Carcinoma: An Underrecognized Problem. *International Journal of Gynecological Pathology*, **2019**, 38, 568-575	3.2	9
138	Genomic Applications in Ovarian Cancer **2019**, 471-482		
137	Prognostic value of progesterone receptor expression in tubo-ovarian high-grade serous carcinoma of the COEUR cohort. *Histopathology*, **2019**, 74, 663-666	7.3	2
136	Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome. *Histopathology*, **2019**, 74, 452-462	7.3	19
135	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. *International Journal of Gynecological Pathology*, **2019**, 38, 119-127	3.2	6
134	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. *International Journal of Gynecological Pathology*, **2019**, 38 Suppl 1, S123-S131	3.2	119
133	Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage. *Journal of the National Cancer Institute*, **2019**, 111, 60-68	9.7	151
132	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14

131	Letter in response to: McAlpine J, Leon-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018; 244: 538-549. *Journal of Pathology*, **2018**, 245, 249-250	9.4	10
130	Cervical Adenocarcinoma: A Comparison of the Reproducibility of the World Health Organization 2003 and 2014 Classifications. *Journal of Lower Genital Tract Disease*, **2018**, 22, 132-138	3.6	3
129	Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. *Histopathology*, **2018**, 73, 299-305	7.3	20
128	High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases. *American Journal of Surgical Pathology*, **2018**, 42, 534-544	6.7	24
127	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. *BMC Cancer*, **2018**, 18, 347	4.8	42
126	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. *Clinical Cancer Research*, **2018**, 24, 569-580	12.9	46
125	Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins. *American Journal of Surgical Pathology*, **2018**, 42, 76-83	6.7	50
124	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
123	You won□t believe this old test □that does cheap single-cell mutation detection. *Journal of Pathology: Clinical Research*, **2018**, 4, 149-153	5.3	5
122	Histotype classification of ovarian carcinoma: A comparison of approaches. *Gynecologic Oncology*, **2018**, 151, 53-60	4.9	30
121	ALK Is a Specific Diagnostic Marker for Inflammatory Myofibroblastic Tumor of the Uterus. *American Journal of Surgical Pathology*, **2018**, 42, 1353-1359	6.7	28
120	Immunohistochemical Profiling of Endometrial Serous Carcinoma. *International Journal of Gynecological Pathology*, **2017**, 36, 128-139	3.2	39
119	Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. *Modern Pathology*, **2017**, 30, 577-586	9.8	88
118	Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles. *Cancer Causes and Control*, **2017**, 28, 447-457	2.8	16
117	Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary. *American Journal of Surgical Pathology*, **2017**, 41, 685-695	6.7	41
116	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. *International Journal of Gynecological Pathology*, **2017**, 36, 555-561	3.2	25
115	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. *American Journal of Surgical Pathology*, **2017**, 41, 245-252	6.7	56
114	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190

113	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2017**, 28, 459-468	2.8	13
112	Combined oral contraceptive use before the first birth and epithelial ovarian cancer risk. *British Journal of Cancer*, **2017**, 116, 265-269	8.7	6
111	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. *Journal of Pathology: Clinical Research*, **2017**, 3, 279-293	5.3	44
110	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
109	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
108	Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei. *International Journal of Gynecological Cancer*, **2017**, 27, 214-222	3.5	3
107	and Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. *Cancer Research*, **2017**, 77, 4268-4278	10.1	32
106	Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma. *Histopathology*, **2017**, 70, 347-358	7.3	17
105	Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	26
104	A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. *Histopathology*, **2017**, 71, 736-742	7.3	19
103	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. *Histopathology*, **2016**, 68, 916-24	7.3	45
102	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. *Modern Pathology*, **2016**, 29, 1586-1593	9.8	59
101	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. *Gynecologic Oncology*, **2016**, 143, 46-53	4.9	94
100	Optimized p53 immunohistochemistry is an accurate predictor of mutation in ovarian carcinoma. *Journal of Pathology: Clinical Research*, **2016**, 2, 247-258	5.3	192
99	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. *Cancer Epidemiology*, **2016**, 45, 119-125	2.8	17
98	Adult lifetime alcohol consumption and invasive epithelial ovarian cancer risk in a population-based case-control study. *Gynecologic Oncology*, **2016**, 140, 277-84	4.9	14
97	Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. *International Journal of Gynecological Cancer*, **2016**, 26, 431-6	3.5	23
96	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. *International Journal of Gynecological Pathology*, **2016**, 35, 430-41	3.2	121

95	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). *Gynecologic Oncology*, **2016**, 141, 148-54	4.9	26
94	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. *Modern Pathology*, **2016**, 29, 302-14	9.8	85
93	Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer. *Gynecologic Oncology*, **2016**, 140, 124-30	4.9	27
92	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. *American Journal of Surgical Pathology*, **2016**, 40, 166-180	6.7	42
91	Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas. *Histopathology*, **2016**, 69, 288-97	7.3	57
90	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience. *International Journal of Gynecological Pathology*, **2016**, 35, 209-21	3.2	24
89	Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours. *Histopathology*, **2016**, 69, 560-9	7.3	42
88	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. *Gynecologic Oncology*, **2016**, 141, 559-563	4.9	19
87	Targeted mutation analysis of endometrial clear cell carcinoma. *Histopathology*, **2015**, 66, 664-74	7.3	63
86	Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. *Gynecologic Oncology*, **2015**, 139, 268-74	4.9	35
85	Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. *Modern Pathology*, **2015**, 28, 505-14	9.8	136
84	Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1 *International Journal of Gynecological Pathology*, **2015**, 34, 323-33	3.2	38
83	Efficient molecular subtype classification of high-grade serous ovarian cancer. *Journal of Pathology*, **2015**, 236, 272-7	9.4	63
82	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination. *International Journal of Gynecological Pathology*, **2015**, 34, 517-27	3.2	10
81	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. *American Journal of Surgical Pathology*, **2015**, 39, 1548-57	6.7	50
80	Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. *American Journal of Surgical Pathology*, **2015**, 39, 357-64	6.7	88
79	Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. *International Journal of Gynecological Cancer*, **2015**, 25, 1187-93	3.5	26
78	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. *Oncotarget*, **2015**, 6, 39088-97	3.3	49

77	Biobanking in the Twenty-First Century: Driving Population Metrics into Biobanking Quality. *Advances in Experimental Medicine and Biology*, **2015**, 864, 95-114	3.6	7
76	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. *Histopathology*, **2014**, 64, 1004-13	7.3	84
75	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. *Gynecologic Oncology*, **2014**, 134, 15-9	4.9	129
74	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. *British Journal of Cancer*, **2014**, 111, 2297-307	8.7	49
73	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1 and oestrogen receptor. *Histopathology*, **2014**, 64, 585-96	7.3	59
72	PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. *Gynecologic Oncology*, **2014**, 132, 188-93	4.9	21
71	New Views of Ovarian Carcinoma Types: How Will This Change Practice? **2014**, 29-38		1
70	Recent alcohol consumption and risk of incident ovarian carcinoma: a pooled analysis of 5,342 cases and 10,358 controls from the Ovarian Cancer Association Consortium. *BMC Cancer*, **2013**, 13, 28	4.8	23
69	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. *Lancet Oncology, The*, **2013**, 14, 853-62	21.7	248
68	Reproducibility of histological cell type in high-grade endometrial carcinoma. *Modern Pathology*, **2013**, 26, 1594-604	9.8	125
67	The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. *Modern Pathology*, **2013**, 26, 1255-63	9.8	38
66	MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. *Gynecologic Oncology*, **2013**, 131, 309-14	4.9	41
65	PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. *Gynecologic Oncology*, **2013**, 128, 409-14	4.9	81
64	Specimen quality evaluation in Canadian biobanks participating in the COEUR repository. *Biopreservation and Biobanking*, **2013**, 11, 83-93	2.1	31
63	Quantification of ER/PR expression in ovarian low-grade serous carcinoma. *Gynecologic Oncology*, **2013**, 128, 371-6	4.9	51
62	Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue. *BioMed Research International*, **2013**, 2013, 815894	3	7
61	Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271. *International Journal of Gynecological Pathology*, **2013**, 32, 176	3.2	
60	Histotype-genotype correlation in 36 high-grade endometrial carcinomas. *American Journal of Surgical Pathology*, **2013**, 37, 1421-32	6.7	92

59	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1677-86	4	53
58	Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review. *Histopathology*, **2013**, 63, 704-12	7.3	5
57	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
56	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. *Journal of Clinical Investigation*, **2013**, 123, 517-25	15.9	371
55	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. *Journal of Translational Medicine*, **2012**, 10, 33	8.5	85
54	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. *Clinical and Experimental Metastasis*, **2012**, 29, 239-52	4.7	41
53	A rare case of NUT midline carcinoma. *Gynecologic Oncology Case Reports*, **2012**, 3, 1-3		20
52	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. *Modern Pathology*, **2012**, 25, 740-50	9.8	113
51	Architectural patterns of ovarian/pelvic high-grade serous carcinoma. *International Journal of Gynecological Pathology*, **2012**, 31, 397-404	3.2	23
50	Type-specific response to neoadjuvant chemotherapy: ovarian high-grade serous carcinoma versus colorectal mucinous carcinoma. *Journal of Obstetrics and Gynaecology Canada*, **2012**, 34, 678-82	1.3	4
49	Molecular Pathology of Ovarian Carcinomas. *Surgical Pathology Clinics*, **2011**, 4, 275-96	3.9	1
48	Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. *Lancet Oncology, The*, **2011**, 12, 1071-80	21.7	102
47	Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. *International Journal of Gynecological Pathology*, **2011**, 30, 366-71	3.2	32
46	Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. *American Journal of Surgical Pathology*, **2011**, 35, 36-44	6.7	105
45	Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. *Gynecologic Oncology*, **2011**, 121, 407-15	4.9	186
44	Calculator for ovarian carcinoma subtype prediction. *Modern Pathology*, **2011**, 24, 512-21	9.8	79
43	Letter to the editor regarding ‘Roh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression’. *Modern Pathology*, **2011**, 24, 1281-2; author reply 1282-3	9.8	6
42	Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. *Annals of Oncology*, **2011**, 22, 341-7	10.3	48

41	Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 1822-30	4	22
40	Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. *American Journal of Surgical Pathology*, **2010**, 34, 984-93	6.7	119
39	Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. *International Journal of Gynecological Pathology*, **2010**, 29, 99-107	3.2	76
38	Differences in tumor type in low-stage versus high-stage ovarian carcinomas. *International Journal of Gynecological Pathology*, **2010**, 29, 203-11	3.2	260
37	High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. *International Journal of Gynecological Pathology*, **2010**, 29, 343-50	3.2	129
36	Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. *Gynecologic Oncology*, **2010**, 116, 50-6	4.9	105
35	Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. *Journal of Pathology*, **2010**, 220, 392-400	9.4	76
34	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. *Journal of Pathology*, **2010**, 222, 191-8	9.4	115
33	Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. *PLoS ONE*, **2009**, 4, e6412	3.7	285
32	Adult-type granulosa cell tumors and FOXL2 mutation. *Cancer Research*, **2009**, 69, 9160-2	10.1	49
31	Dicer and Drosha in ovarian cancer. *New England Journal of Medicine*, **2009**, 360, 1150-1; author reply 1151	59.2	7
30	HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. *BMC Cancer*, **2009**, 9, 433	4.8	141
29	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. *Modern Pathology*, **2009**, 22, 469-75	9.8	102
28	Mutation of FOXL2 in granulosa-cell tumors of the ovary. *New England Journal of Medicine*, **2009**, 360, 2719-29	59.2	551
27	A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. *American Journal of Surgical Pathology*, **2009**, 33, 14-21	6.7	181
26	Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. *Applied Immunohistochemistry and Molecular Morphology*, **2009**, 17, 375-82	1.9	31
25	The fallopian tube: primary site of most pelvic high-grade serous carcinomas. *International Journal of Gynecological Cancer*, **2009**, 19, 58-64	3.5	147
24	Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. *Neoplasia*, **2008**, 10, 1021-7	6.4	123

23	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. *Human Pathology*, **2008**, 39, 1239-51	3.7	207
22	Critical molecular abnormalities in high-grade serous carcinoma of the ovary. *Expert Reviews in Molecular Medicine*, **2008**, 10, e22	6.7	42
21	Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. *PLoS ONE*, **2008**, 3, e3409	3.7	35
20	Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. *PLoS Medicine*, **2008**, 5, e232	11.6	575
19	Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues. *International Journal of Cancer*, **2007**, 120, 2393-400	7.5	18
18	Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma. *Oncogene*, **2007**, 26, 7584-9	9.2	83
17	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. *BMC Medicine*, **2007**, 5, 33	11.4	44
16	Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. *International Journal of Gynecological Pathology*, **2006**, 25, 121-30	3.2	49
15	Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. *Modern Pathology*, **2006**, 19, 581-7	9.8	48
14	Influence of various cytokines on adhesion and migration of the colorectal adenocarcinoma cell line HRT-18. *Oncology*, **2005**, 68, 33-9	3.6	6
13	Activation of mitogen-activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. *American Journal of Pathology*, **2005**, 167, 879-85	5.8	20
12	Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis. *British Journal of Cancer*, **2005**, 92, 1729-36	8.7	21
11	Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation. *Anticancer Research*, **2005**, 25, 3431-6	2.3	12
10	Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. *Cancer Research*, **2004**, 64, 189-95	10.1	143
9	Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. *British Journal of Cancer*, **2004**, 90, 815-21	8.7	139
8	Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2004**, 445, 456-64	5.1	41
7	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. *Cancer*, **2003**, 97, 2978-87	6.4	176
6	Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. *Oncogene*, **2003**, 22, 8653-61	9.2	85

5	Regulation of cell growth and the expression of extracellular matrix proteins in colorectal adenocarcinoma: a fibroblast-tumor cell coculture model to study tumor-host interactions in vitro. *European Journal of Cell Biology*, **2003**, 82, 1-8	6.1	28
4	Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. *Cancer Letters*, **2003**, 195, 101-9	9.9	17
3	Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. *American Journal of Pathology*, **2002**, 160, 893-903	5.8	175
2	Interleukin-10 in serous ovarian carcinoma cell lines. *Cancer Immunology, Immunotherapy*, **2001**, 50, 328-33	7.4	21
1	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma		1